Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma

<p><i>Nf2</i> loss results in Ras<sup>G12D</sup>-induced oncogenesis and cooperates with <i>Trp53</i> loss to accelerate ICC formation. <b>A,</b> Kaplan–Meier curve demonstrating the relative survival proportions of mice with KRAS<sup>G12D&...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Nicholas T. Younger (14956251) (author)
مؤلفون آخرون:	Mollie L. Wilson (14956254) (author), Anabel Martinez Lyons (14956257) (author), Edward J. Jarman (9773166) (author), Alison M. Meynert (14956260) (author), Graeme R. Grimes (14160170) (author), Konstantinos Gournopanos (14956263) (author), Scott H. Waddell (14956266) (author), Peter A. Tennant (14956269) (author), David H. Wilson (14956272) (author), Rachel V. Guest (14956275) (author), Stephen J. Wigmore (14915943) (author), Juan Carlos Acosta (14956278) (author), Timothy J. Kendall (14956281) (author), Martin S. Taylor (14956284) (author), Duncan Sproul (13971883) (author), Pleasantine Mill (256953) (author), Luke Boulter (14956287) (author)
منشور في:	2025
الموضوعات:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Signaling Computational Methods Sequence analysis Drug Targets Gastrointestinal Cancers Liver cancer Gene Technologies Comparative genomics Oncogenes & Tumor Suppressors Kras Preclinical Models Animal models of cancer
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
حسب: Nicholas T. Younger (14956251)
منشور في: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
حسب: Nicholas T. Younger (14956251)
منشور في: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
حسب: Nicholas T. Younger (14956251)
منشور في: (2025)

Supplementary Table S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
حسب: Queralt Serra-Camprubí (15050174)
منشور في: (2025)

Supplementary Table S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
حسب: Queralt Serra-Camprubí (15050174)
منشور في: (2025)

Supplementary Table S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
حسب: Queralt Serra-Camprubí (15050174)
منشور في: (2025)

Supplementary Table S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
حسب: Queralt Serra-Camprubí (15050174)
منشور في: (2025)

Supplementary Table S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
حسب: Queralt Serra-Camprubí (15050174)
منشور في: (2025)

Supplementary Tables from <i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
حسب: Elisa ten Hacken (15136187)
منشور في: (2025)

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Supplementary Table S3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
حسب: Ernesto Gargiulo (15134961)
منشور في: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Table 1 from Addressing Common Misuses and Pitfalls of <i>P</i> values in Biomedical Research
حسب: Ming Wang (8809334)
منشور في: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
حسب: Yemin Wang (17315078)
منشور في: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
حسب: Caleb N. Seavey (15056489)
منشور في: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
حسب: Caleb N. Seavey (15056489)
منشور في: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
حسب: Yuncheng Bei (16546095)
منشور في: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
حسب: Yuncheng Bei (16546095)
منشور في: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
حسب: Yuncheng Bei (16546095)
منشور في: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
حسب: Zhihang Chen (17315678)
منشور في: (2025)

Supplementary Data from Genetic Modulation of <i>BET1L</i> Confers Colorectal Cancer Susceptibility by Reducing miRNA Binding and m<sup>6</sup>A Modification
حسب: Shuwei Li (16437116)
منشور في: (2025)

Figure S1 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
حسب: Subhamoy Chakraborty (16648124)
منشور في: (2025)

Figure S2 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
حسب: Subhamoy Chakraborty (16648124)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_blvokujftr4ptq27te88a3jv8k